OSU-03012 interacts with lapatinib to kill brain cancer cells

Cancer Biology and Therapy

Volumn 13, Issue 14, 2012, Pages 1501-1511

  Booth, Laurence ^a   Cruickshanks, Nichola ^a   Ridder, Thomas ^a   Chen, Ching Shih ^b   Grant, Steven ^a   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Autophagy; ERBB1; Glioblastoma; Lapatinib; Medulloblastoma; OSU 03012; PTEN

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; AUTOPHAGY PROTEIN 5; BECLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAS ANTIGEN; HEAT SHOCK PROTEIN 90; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; S6 KINASE; TANESPIMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LETHALITY; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BENZOQUINONES; BRAIN NEOPLASMS; CELL LINE, TUMOR; DRUG SYNERGISM; GENES, ERBB-1; HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LIPIDS; MAP KINASE KINASE 1; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PTEN PHOSPHOHYDROLASE; PYRAZOLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84870695988     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22275     Document Type: Article

References (28)

1. Hawkey CJ, Fortun PJ. Cyclooxygenase-2 inhibitors. Curr Opin Gastroenterol 2005; 21:660-4; PMID:16220041.
2. Kiefer W, Dannhardt G. Novel insights and therapeutical applications in the field of inhibitors of COX-2. Curr Med Chem 2004; 11:3147-61; PMID:15579005.
3. Kang SG, Kim JS, Park K, Kim JS, Groves MD, Nam DH. Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncol Rep 2006; 15:7-13; PMID:16328028.
4. Klenke FM, Gebhard MM, Ewerbeck V, Abdollahi A, Huber PE, Sckell A. The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer 2006; 6:9; PMID:16409625; http://dx.doi.org/10.1186/1471-2407-6-9.
5. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol 2004; 31(Suppl 7):12-21; PMID:15252926; http://dx.doi.org/10.1053/j.seminoncol. 2004.03.041.
6. Cui W, Yu CH, Hu KQ. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 2005; 11:8213-21; PMID:16299255; http://dx.doi.org/10.1158/1078- 0432.CCR-05-1044.
7. Kashfi K, Rigas B. Is COX-2 a 'collateral' target in cancer prevention? Biochem Soc Trans 2005; 33:724-7; PMID:16042585; http://dx.doi.org/10.1042/ BST0330724.
8. Narayanan BA, Narayanan NK, Pttman B, Reddy BS. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. Prostate 2006; 66:257-65; PMID:16175586; http://dx.doi.org/10.1002/pros.20331.
9. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2- independent mechanism. Clin Cancer Res 2005; 11:1999-2007; PMID:15756026; http://dx.doi.org/10.1158/1078-0432.CCR-04-1877.
10. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, et al. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004; 64:1444-51; PMID:14973075; http://dx.doi.org/10.1158/0008-5472. CAN-03-2396.
11. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble JW, Shiau CW, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide- dependent protein kinase-1 inhibitors. Cancer Res 2004; 64:4309-18; PMID:15205346; http://dx.doi.org/10.1158/0008-5472.CAN-03-4063.
12. Park MA, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan MP, et al. OSU-03012 stimulates PKRlike endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol 2008; 73:1168-84; PMID:18182481; http://dx.doi.org/10.1124/mol. 107.042697.
13. Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, et al. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 2006; 70:589-603; PMID:16622074; http://dx.doi.org/10.1124/mol.106.025007.
14. Booth L, Cazanave SC, Hamed HA, Yacoub A, Ogretmen B, Chen CS, et al. OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing. Cancer Biol Ther 2012; 13:224-36; PMID:22354011; http://dx.doi.org/10.4161/cbt.13.4.18877.
15. Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, et al. Radiation-induced cell signaling: insideout and outside-in. Mol Cancer Ther 2007; 6:789-801; PMID:17363476; http://dx.doi.org/10.1158/1535-7163.MCT-06-0596.
16. Berezowska S, Schlegel J. Targeting ErbB receptors in high-grade glioma. Curr Pharm Des 2011; 17:2468-87; PMID:21827413; http://dx.doi.org/10.2174/ 138161211797249233.
17. Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 2012; 23:765-76; PMID:22824822; http://dx.doi.org/10.1097/CAD.0b013e328352d292.
18. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012; 26:756-84; PMID:22508724; http://dx.doi.org/10.1101/gad.187922.112.
19. Massimino M, Giangaspero F, Garrè ML, Gandola L, Poggi G, Biassoni V, et al. Childhood medulloblastoma. Crit Rev Oncol Hematol 2011; 79:65-83; PMID:21129995; http://dx.doi.org/10.1016/j.critrevonc.2010.07.010.
20. Walker T, Mitchell C, Park MA, Yacoub A, Rahmani M, Häussinger D, et al. 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species. Mol Cancer Ther 2010; 9:1378-95; PMID:20442308; http://dx.doi.org/10.1158/1535-7163.MCT-09-1131.
21. Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des 2012; 18:2766-77; PMID:22475451; http://dx.doi.org/10.2174/ 138161212800626210.
22. Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 2011; 20:1397-411; PMID:21851287; http://dx.doi.org/10.1517/13543784.2011.609167.
23. Camara-Quintana JQ, Nitta RT, Li G. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT. Neurosurg Clin N Am 2012; 23:237-46, viii; PMID:22440867; http://dx.doi.org/10.1016/j.nec.2012.01.011.
24. Alers S, Löffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol 2012; 32:2-11; PMID:22025673; http://dx.doi.org/10.1128/MCB.06159-11.
25. Shen S, Kepp O, Kroemer G. The end of autophagic cell death? Autophagy 2012; 8:1-3; PMID:22082964; http://dx.doi.org/10.4161/auto.8.1.16618.
26. Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, et al. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. J Biol Chem 2008; 283:24343-58; PMID:18614532; http://dx.doi.org/10.1074/jbc.M803444200.
27. Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, et al. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 2008; 7:1648-62; PMID:18787411; http://dx.doi.org/10.4161/cbt.7.10.6623.
28. Höland K, Salm F, Arcaro A. The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors. Curr Cancer Drug Targets 2011; 11:894-918; PMID:21861842; http://dx.doi.org/10.2174/ 156800911797264743.